Intralesional corticosteroid injections for infantile hemangioma

Abstract

Infantile hemangiomas (IHs) are the most common benign soft-tissue tumors in infancy; about 10%–15% of them may result in various complications that require active management. The current first-line treatment for IH is oral propranolol; however, some studies recommend intralesional corticosteroid injections for small, limited, deep, or prominent tumors because of concern regarding serious systemic complications related to propranolol. This review summarizes and analyzes the current clinical studies on corticosteroid injections in IHs, discusses treatment norms, and explores future research directions.